Key Finding:
Next-generation sequencing can define characteristic differences in the genomic landscape across SSTR subtypes in high-grade and low-grade neuroendocrine neoplasms. Incorporating the molecular profiling of neuroendocrine neoplasms can thus aid in advancing the development of more tailored therapeutic strategies.